1st Quarter - Report

MERCK & CO, INC. for MERCK & CO INC

Firm
Client
Income
—
Expenses
$2,110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1128 (114th)

Medicare/Medicaid MMM

Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (H.R. 2, the Medicare Access and CHIP Reauthorization Act), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
JENELLE KRISHNAMOORTHY New 2004-2006 - Environment,science, technology and health officer, bureau of South Asia, U.S. State Dept. 2006-2009 - Health Legislative Assistant, Senator Tom Harkin 2010-2015 - Health Policy Director, Senate HELP Committee
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5780 (114th), H.R. 2 (114th)

Copyright/Patent/Trademark CPT

Intellectual property (general education), patent reform (H.R. 3309, the Innovation Act, S.632, the STRONG Patents Act)

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 632 (114th), H.R. 3309 (114th)

Health Issues HCR

340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), DISARM (H.R. 4187), ACA Implementation (no specific bill), biosimilars (no specific bill), 21st Century Cures, Medical Innovation Act (S.320), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
JENELLE KRISHNAMOORTHY New 2004-2006 - Environment,science, technology and health officer, Bureau of South Asia, U.S. State Dept. 2006-2009 - Health Legislative Assistant, Senator Tom Harkin 2010-2015 - Health Policy Director, Senate HELP committee
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4187 (114th), S. 320 (114th)

Budget/Appropriations BUD

House of Representatives FY16 Budget Resolution, Senate FY16 Budget Resolution,

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Animals ANI

Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)

LobbyistCovered position, as disclosed
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.